Becton Dickinson & Company (BD) Bags IMAPAC’s Asia Bioprocessing Excellence Award 2022 and Recognized as The Best Bioprocessing Supplier Award: Formulation & Delivery Innovation
SINGAPORE – IMAPAC – 31 March 2022
BD, one of the largest global medical technology companies, has bagged the Asia Bioprocessing Excellence Award (ABEA) 2022 under the category Bioprocessing Supplier Award: Formulation & Delivery Innovation. The ABEA 2022 Ceremony was held in conjunction with the 9th Biologics Manufacturing Asia and 6th Biologistics World Asia 2022 hybrid conference, streamed live on 29 – 30 March 2022. The event was organized and hosted by a Singapore-based biopharmaceutical media and consulting firm, IMAPAC.
BD was chosen as a winner in this category based on their performance against three key strategic imperatives in the formulation & drug delivery market: transformative mega trends post-pandemic & new business models, increase in efforts and investments made to the fill & finish bioprocessing segment, expansion of a suite of products and services since 2021. With over 60 years of expertise in drug delivery, BD with a brand heritage, has proved to be a thought leader, serving beyond 500 companies across the globe, providing solutions for over 70% of pharmaceutical companies, catering to 100 molecules with various therapeutic areas in focus.
Preeti Bisht, Research Analyst from IMAPAC’s Market Intelligence commented: “BD’s flexible and wide range of product portfolio and formulation services has enabled them in offering a comprehensive solution for every custom drug delivery need. BD intends to make the process seamless for combination products by expanding its services capabilities through the acquisition of ZebraSci (a pharmaceutical manufacturing and testing company, acquired by BD in Aug 2021).”
Through the recent acquisition of ZebraSci, BD expands its focus on the combination products with services including – Primary container & device selection and evaluation, Small-scale fill & finish and assembly (NFHU), Drug combination product design & Verification. BD also continues to enhance services to support Pharma in their regulatory approval process.
BD has a keen eye on expanding CMO capabilities in Asia. In Q4 2021, BD signed a MOU with Taiwanese Adimmune, a vaccine supplier in Asia with cGMP certification from the US, EU, China, Korea, and Taiwan. The two parties collaborate to strengthen their CMO capabilities and help expedite vaccine contract manufacturing in Asia. As recent as March 2022, BD, signing a memorandum with Taiyo Pharmatech (CDMO), strives to provide PFS formulation (prefilled syringe formulation) total support service to pharmaceutical companies in Japan and overseas.
Terence Chui, Senior Manager, Customer and Services Marketing Asia-Pacific from BD, on receiving the award said, “We are very proud to receive IMAPAC’s ABEA 2022 for the Formulations and Delivery Innovation category, as this is an affirmation that our end users, both clinicians, and patients, continue to trust us in delivering products that are safe, effective and innovative. Together, we ensure that life-changing pharmaceuticals such as biologics and biosimilars are made accessible to millions of patients in our region. During the COVID-19 pandemic, we have worked with many of our pharmaceutical partners to ensure a stable supply of drugs delivery devices intending to meet the needs in the Asia Pacific market. In the coming years, we’ll continue our efforts in adding capabilities and capacities to our supply network, delivery innovations as well as support services to meet the ever-changing health care landscape.”
The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
IMAPAC, the organizing committee of ABEA 2022 called for nomination from the APAC bioprocessing community, comprising 20,000+ participants for different bioprocessing award categories. All entries and nominations were considered and submitted to the judging panel, comprising 3 industry experts. Based on the number of nominations and assessment, the top 5 entries under each category were shortlisted from the top 5 entries, the award winner was determined by 1000 voting results from the public or bioprocessing community.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. Over the past decade, they have been facilitating companies expand their influence, their influence, make data driven decisions through industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking.